237 related articles for article (PubMed ID: 6803810)
1. Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and alpha-substituted catecholamines.
Gordonsmith RH; Raxworthy MJ; Gulliver PA
Biochem Pharmacol; 1982 Feb; 31(3):433-7. PubMed ID: 6803810
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
Lautala P; Ulmanen I; Taskinen J
Mol Pharmacol; 2001 Feb; 59(2):393-402. PubMed ID: 11160877
[TBL] [Abstract][Full Text] [Related]
3. Catechol-O-methyltransferase: substrate-specificity and stereoselectivity for beta-adrenoceptor agents.
Raxworthy MJ; Youde IR; Gulliver PA
Xenobiotica; 1986 Jan; 16(1):47-52. PubMed ID: 2868577
[TBL] [Abstract][Full Text] [Related]
4. The effect of ring-fluorination on the rate of O-methylation of dihydroxyphenylalanine (DOPA) by catechol-O-methyltransferase: significance in the development of 18F-PETT scanning agents.
Creveling CR; Kirk KL
Biochem Biophys Res Commun; 1985 Aug; 130(3):1123-31. PubMed ID: 3927916
[TBL] [Abstract][Full Text] [Related]
5. Catechol-O-methyltransferase inhibition in erythrocytes and liver by BIA 3-202 (1-[3,4-dibydroxy-5-nitrophenyl]-2-phenyl-ethanone).
Soares-da-Silva P; Vieira-Coelho MA; Parada A
Pharmacol Toxicol; 2003 Jun; 92(6):272-8. PubMed ID: 12787259
[TBL] [Abstract][Full Text] [Related]
6. Salvianolic acid B as a substrate and weak catechol-O-methyltransferase inhibitor in rats.
Qi Q; Cao L; Li F; Wang H; Liu H; Hao H; Hao K
Xenobiotica; 2015; 45(9):820-7. PubMed ID: 25869243
[TBL] [Abstract][Full Text] [Related]
7. Conjoint radioenzymatic measurement of catecholamines, their catechol metabolites and DOPA in biological samples.
Thiede HM; Kehr W
Naunyn Schmiedebergs Arch Pharmacol; 1981 Dec; 318(1):19-28. PubMed ID: 6799844
[TBL] [Abstract][Full Text] [Related]
8. The metabolism of dopamine, NN-dialkylated dopamines and derivatives of the dopamine agonist 2-amino-dihydroxy-1,2,3,4-tetrahydronaphthalene (ADTN) by catechol-O-methyltransferase.
Youde IR; Raxworthy MJ; Gulliver PA; Dijkstra D; Horn AS
J Pharm Pharmacol; 1984 May; 36(5):309-13. PubMed ID: 6145766
[TBL] [Abstract][Full Text] [Related]
9. Methoxytyrosine formation as an indicator of catechol-O-methyltransferase activity in rat liver in vivo.
Kehr W; Zimmermann R; Thiede M
Naunyn Schmiedebergs Arch Pharmacol; 1977 Oct; 300(1):19-23. PubMed ID: 593428
[TBL] [Abstract][Full Text] [Related]
10. Characterization of SafC, a catechol 4-O-methyltransferase involved in saframycin biosynthesis.
Nelson JT; Lee J; Sims JW; Schmidt EW
Appl Environ Microbiol; 2007 Jun; 73(11):3575-80. PubMed ID: 17449703
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the catechol-O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by catecholamine: implications for the mechanism of estrogen-induced carcinogenesis.
Zhu BT; Liehr JG
Arch Biochem Biophys; 1993 Jul; 304(1):248-56. PubMed ID: 8323288
[TBL] [Abstract][Full Text] [Related]
12. BIA 3-202, a novel catechol-O-methyltransferase inhibitor, reduces the peripheral O-methylation of L-DOPA and enhances its availability to the brain.
Parada A; Soares-da-Silva P
Pharmacology; 2003 May; 68(1):29-37. PubMed ID: 12660477
[TBL] [Abstract][Full Text] [Related]
13. Compartmental analysis of dopa decarboxylation in living brain from dynamic positron emission tomograms.
Cumming P; Gjedde A
Synapse; 1998 May; 29(1):37-61. PubMed ID: 9552174
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme.
Lotta T; Vidgren J; Tilgmann C; Ulmanen I; Melén K; Julkunen I; Taskinen J
Biochemistry; 1995 Apr; 34(13):4202-10. PubMed ID: 7703232
[TBL] [Abstract][Full Text] [Related]
15. Irreversible inhibition of aromatic-L-amino acid decarboxylase by alpha-difluoromethyl-DOPA and metabolism of the inhibitor.
Ribéreau-Gayon G; Palfreyman MG; Zraïka M; Wagner J; Jung MJ
Biochem Pharmacol; 1980 Sep; 29(18):2465-9. PubMed ID: 7426053
[No Abstract] [Full Text] [Related]
16. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
17. Enzymatic O-methylation of catechols and catecholamines.
Schüsler-Van Hees MT; Beijersbergen Van Henegouwen GM
Pharm Weekbl Sci; 1982 Dec; 4(6):176-82. PubMed ID: 7155787
[TBL] [Abstract][Full Text] [Related]
18. Enantioselectivity in the methylation of the catecholic phase I metabolites of methylenedioxy designer drugs and their capability to inhibit catechol-O-methyltransferase-catalyzed dopamine 3-methylation.
Meyer MR; Maurer HH
Chem Res Toxicol; 2009 Jun; 22(6):1205-11. PubMed ID: 19462939
[TBL] [Abstract][Full Text] [Related]
19. L-dopa as substrate for human duodenal catechol-O-methyltransferase and aromatic L-amino acid decarboxylase.
Schultz E
Biomed Chromatogr; 1990 Nov; 4(6):242-4. PubMed ID: 2289048
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic L-DOPA administration of catecholamine metabolism in the rat.
Lancaster J; Sawyer PR; Shepherd DM; Turnbull MJ
Br J Pharmacol; 1973 Apr; 47(4):838-42. PubMed ID: 4723802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
